Quick answers
- What is Zolmitriptan used for?
- The FDA-approved label (Zolmitriptan, Amneal Pharmaceuticals NY LLC, April 30, 2019) says: “ZOLMITRIPTAN NASAL SPRAY is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older. Limitations of Use Only use ZOLMITRIPTAN NASAL SPRAY if a clear diagnosis of migraine has been established. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Zolmitriptan have a boxed warning?
- No. None of the 26 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Zolmitriptan?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Zolmitriptan been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Zolmitriptan?
- 20 companies list prescription products of Zolmitriptan in the FDA NDC Directory, including Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited and Glenmark Pharmaceuticals Inc., USA.
What Zolmitriptan is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
ZOLMITRIPTAN NASAL SPRAY is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older. Limitations of Use Only use ZOLMITRIPTAN NASAL SPRAY if a clear diagnosis of migraine has been established. …
— FDA label: Zolmitriptan, Amneal Pharmaceuticals NY LLC, effective April 30, 2019. Read the full label on DailyMed →
The FDA has 26 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 26 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet, film coated · Tablet, orally disintegrating · Tablet · Spray · Spray, metered |
|---|---|
| Route | Oral · Nasal |
| Prescription products | 46 in the FDA NDC Directory |
| Brand names | Zolmitriptan Od, Zolmiptriptan, Zomig |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| zolmitriptan 2.5 mg tablet | Generic | $0.9324 per tablet |
| zolmitriptan 2.5 mg tablet, film coated | Generic | $0.9324 per tablet |
| zolmitriptan 2.5 mg tablet, orally disintegrating | Generic | $2.28 per tablet |
| zolmitriptan 5 mg spray | Generic | $47.99 per unit |
| zolmitriptan 5 mg spray, metered | Generic | $47.99 per unit |
| zolmitriptan 5 mg tablet | Generic | $1.34 per tablet |
| zolmitriptan 5 mg tablet, film coated | Generic | $1.34 per tablet |
| zolmitriptan 5 mg tablet, orally disintegrating | Generic | $3.66 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Alembic Pharmaceuticals Inc.4 products
- Alembic Pharmaceuticals Limited4 products
- Glenmark Pharmaceuticals Inc., USA4 products
- Bryant Ranch Prepack3 products
- Medstone Pharma LLC2 products
- Aurobindo Pharma Limited2 products
- Zydus Pharmaceuticals USA Inc.2 products
- Rising Pharma Holdings, Inc.2 products
- Direct_Rx2 products
- Asclemed USA, Inc.2 products
- Jubilant Cadista Pharmacuticals Inc.2 products
- Cipla USA Inc.2 products
- AvKARE2 products
- Zydus Lifesciences Limited2 products
- Ajanta Pharma USA Inc.2 products
- BluePoint Laboratories2 products
- Amneal Pharmaceuticals NY LLC2 products
- Amneal Pharmaceuticals LLC2 products
- PLD Acquisitions LLC DBA Avma Pharma Solutions2 products
- Padagis Israel Pharmaceuticals Ltd1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA021450 ZOMIG | Amneal | September 30, 2003 | 5, latest December 21, 2018 2018: Labeling · 2015: Efficacy · 2013: Efficacy |
Generic approvals (11)
- ANDA201779Glenmark Pharms Ltd · May 14, 2013
- ANDA202560Glenmark Pharms Ltd · May 14, 2013
- ANDA202890Zydus Pharms USA Inc · May 15, 2013
- ANDA204284Invagen Pharms · April 9, 2014
- ANDA202956Jubilant Generics · September 17, 2015
- ANDA204232Alembic · September 30, 2015
- ANDA207021Aurobindo Pharma · May 11, 2016
- ANDA204041Ajanta Pharma Ltd · May 20, 2016
- ANDA205074Alembic · December 1, 2016
- ANDA207867Pld Acquisitions LLC · February 27, 2017
- ANDA212469Padagis Israel · September 30, 2021
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Zolmitriptan, Amneal Pharmaceuticals NY LLC, effective April 30, 2019; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →